Aura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 million - AURA News | RalliesAura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 million
A
AURA• Q2 loss widens as R&D and G&A rise
- Aura Biosciences posted a wider Q2 net loss of USD 45.6 million, with loss per share at USD 0.48.
- R&D expense climbed 34.35% to USD 30.75 million, driven by CoMpass Phase 3 clinical and CRO costs plus bel-sar manufacturing.
- G&A expense more than doubled to USD 17.32 million, on higher stock-based compensation tied to executive transitions plus higher professional fees.
- Cash, cash equivalents, and marketable securities totaled USD 323.8 million at June 30, extending projected cash runway into 1H 2029.
- The Phase 3 CoMpass trial was fully enrolled with 108 patients; topline data from the 15-month primary endpoint remains on track for 2H 2027.
